Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

View Full Paper
Ask AI
Bookmark
Share

Authors

BKBhavna KumarRHRohan HerurLSLaura Samples

Discussion

Loading...

Member takes

Overview

Analysis shows BTK inhibitors cause mobilization of CLL subclones within the bone marrow and lymph nodes, suggesting treatment impact.

Key Points

  • Mobilization of CLL subclones was observed with BTK inhibitors, indicating significant shifts in compartmentalization.
  • Treatment increased lymphocyte counts with notable effects on CLL subclones, including TP53 mutations during the process.
  • Whole exome sequencing was utilized to analyze CLL patients' compartmental shifts between bone marrow and peripheral blood.
  • These findings highlight the complexity in CLL subclones across anatomical sites, emphasizing treatment responses and resistance.

Cite This Study

Kumar et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfd9https://doi.org/10.1182/blood-2025-7406
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systematic molecular profiling to identify determinants of response to ibrutinib2025
  2. 2Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025
  3. 3Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers2025 · 1 citations
  4. 4Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia2025
  5. 5Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies2025